HC Wainwright & Co. Reiterates Buy on ADMA Biologics, Raises Price Target to $7.5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on ADMA Biologics (NASDAQ:ADMA) and increased the price target from $6 to $7.5.
March 26, 2024 | 10:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ADMA Biologics' Buy rating was reiterated by HC Wainwright & Co., with a raised price target from $6 to $7.5.
The reiteration of a Buy rating combined with an increased price target typically signals a positive outlook on the stock by analysts, which can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100